{
    "topic": "coronavirus",
    "source": "Time Magazine",
    "bias": 0,
    "url": "https://time.com/5854219/uk-researchers-drug-covid-survival/",
    "title": "U.K. Researchers Say They Have Found First Drug that Improves COVID-19 Survival",
    "date": "",
    "authors": "Marilynn Marchione",
    "content": "Researchers in England say they have the first evidence that a drug can improve COVID-19 survival : A steroid called dexamethasone reduced deaths by up to one third in severely ill hospitalized patients .\nResults were announced Tuesday and researchers said they would publish them soon . The study is a large , strict test that randomly assigned 2,104 patients to get the drug and compared them with 4,321 patients getting only usual care .\nThe drug was given either orally or through an IV . It reduced deaths by 35 % in patients who needed treatment with breathing machines and by 20 % in those only needing supplemental oxygen . It did not appear to help less ill patients .\n\u201c This is an extremely welcome result , \u201d one study leader , Peter Horby of the University of Oxford , said in a statement . \u201c The survival benefit is clear and large in those patients who are sick enough to require oxygen treatment , so dexamethasone should now become standard of care in these patients . Dexamethasone is inexpensive , on the shelf , and can be used immediately to save lives worldwide . \u201d\nThis is the same study that earlier this month showed the malaria drug hydroxychloroquine was not working against the coronavirus . The study enrolled more than 11,000 patients in England , Scotland , Wales and Northern Ireland who were given either standard of care or that plus one of several treatments : the HIV combo drug lopinavir-ritonavir , the antibiotic azithromycin ; the steroid dexamethasone , the anti-inflammatory drug tocilizumab , or plasma from people who have recovered from COVID-19 that contains antibodies to fight the virus .\nResearch is continuing on the other treatments . The research is funded by government health agencies in the United Kingdom and private donors including the Bill and Melinda Gates Foundation .\nGet our Space Newsletter . Sign up to receive the week 's news in space . Please enter a valid email address . Sign Up Now Check the box if you do not wish to receive promotional offers via email from TIME . You can unsubscribe at any time . By signing up you are agreeing to our Terms of Use and Privacy Policy Thank you ! For your security , we 've sent a confirmation email to the address you entered . Click the link to confirm your subscription and begin receiving our newsletters . If you do n't get the confirmation within 10 minutes , please check your spam folder .",
    "content_original": "Researchers in England say they have the first evidence that a drug can improve COVID-19 survival: A steroid called dexamethasone reduced deaths by up to one third in severely ill hospitalized patients.\n\nResults were announced Tuesday and researchers said they would publish them soon. The study is a large, strict test that randomly assigned 2,104 patients to get the drug and compared them with 4,321 patients getting only usual care.\n\nThe drug was given either orally or through an IV. It reduced deaths by 35% in patients who needed treatment with breathing machines and by 20% in those only needing supplemental oxygen. It did not appear to help less ill patients.\n\n\u201cThis is an extremely welcome result,\u201d one study leader, Peter Horby of the University of Oxford, said in a statement. \u201cThe survival benefit is clear and large in those patients who are sick enough to require oxygen treatment, so dexamethasone should now become standard of care in these patients. Dexamethasone is inexpensive, on the shelf, and can be used immediately to save lives worldwide.\u201d\n\nThis is the same study that earlier this month showed the malaria drug hydroxychloroquine was not working against the coronavirus. The study enrolled more than 11,000 patients in England, Scotland, Wales and Northern Ireland who were given either standard of care or that plus one of several treatments: the HIV combo drug lopinavir-ritonavir, the antibiotic azithromycin; the steroid dexamethasone, the anti-inflammatory drug tocilizumab, or plasma from people who have recovered from COVID-19 that contains antibodies to fight the virus.\n\nResearch is continuing on the other treatments. The research is funded by government health agencies in the United Kingdom and private donors including the Bill and Melinda Gates Foundation.\n\nGet our Space Newsletter. Sign up to receive the week's news in space. Please enter a valid email address. Sign Up Now Check the box if you do not wish to receive promotional offers via email from TIME. You can unsubscribe at any time. By signing up you are agreeing to our Terms of Use and Privacy Policy Thank you! For your security, we've sent a confirmation email to the address you entered. Click the link to confirm your subscription and begin receiving our newsletters. If you don't get the confirmation within 10 minutes, please check your spam folder.\n\nContact us at editors@time.com.",
    "source_url": "www.time.com",
    "bias_text": "left",
    "ID": "PxEzL2fCDGOEPj2j"
}